Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29138572 | 1.00 | KDM4E (0.47) | KDM4ESLC18A3SIGMAR1ALDH1A1GPR119 | |
| SCHEMBL29914114 | 1.00 | KDM4E (0.47) | KDM4ESLC18A3SIGMAR1ALDH1A1GPR119 | |
| SCHEMBL31096201 | 0.81 | KCNK3 (0.48) | GPR119HSD11B1 | |
| SCHEMBL18418205 | 0.80 | KCNK3 (0.48) | GPR119HSD11B1 | |
| SCHEMBL3538916 | 0.80 | KCNK3 (0.52) | GPR119KMT2AHSD11B1OPRM1 | |
| SCHEMBL22569544 | 0.80 | KCNK3 (0.52) | GPR119KMT2AHSD11B1OPRM1 | |
| SCHEMBL23053901 | 0.80 | KCNK3 (0.52) | GPR119KMT2AHSD11B1OPRM1 | |
| SCHEMBL19549750 | 0.79 | SLC18A3 (0.50) | KDM4ESLC18A3SIGMAR1ALDH1A1MEN1 | |
| SCHEMBL19549747 | 0.79 | SLC18A3 (0.50) | KDM4ESLC18A3SIGMAR1ALDH1A1MEN1 | |
| SCHEMBL19549748 | 0.79 | SLC18A3 (0.50) | KDM4ESLC18A3SIGMAR1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4305037-B1 | KRAS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-20240217982-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-04 | — | — | US | disclosed |
| EP-4305037-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117177976-A | KRAS inhibitors | 百时美施贵宝公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192790-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217982-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KDM4E 2597/4885SLC18A3 4788/4885SIGMAR1 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.